Your browser doesn't support javascript.
Epidemiological aspects of headache after different types of COVID-19 vaccines: An online survey.
Magdy, Rehab; Khedr, Diana; Yacoub, Osama; Attia, Abeer; Abdelrahman, Mona A; Mekkawy, Doaa.
  • Magdy R; Department of Neurology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Khedr D; Department of Neurology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Yacoub O; Department of Neurology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Attia A; Department of Public Health and Community Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Abdelrahman MA; Department of Clinical Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
  • Mekkawy D; Department of Neurology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Headache ; 62(8): 1046-1052, 2022 09.
Article in English | MEDLINE | ID: covidwho-2019281
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) vaccine-related side effects are a key concern with the emergence of various types of vaccines in the market. We aimed to assess the frequency and characteristics of headache following different types of COVID-19 vaccines.

METHODS:

Fully vaccinated people were recruited by a convenience sample through an online survey from September 1 to December 1, 2021. Detailed analysis of headache following vaccination was investigated. Participants with a history of pre-existing headaches were telephone interviewed by a neurologist to ascertain the type of headache.

RESULTS:

A total of 1372 participants participated (mean age 32.9 ± 11.1). The highest frequency of headache was reported with the adenoviral vector type (302/563, 53.6%), followed by mRNA vaccines (129/269, 48%) and then the inactivated type (188/540, 34.8%). Recipients of the adenoviral vector type had a significantly longer latency between vaccination and the headache onset (median 8 h [512]) than recipients of the inactivated type (median 4 h [28], p < 0.001). Headache intensity was significantly higher with the adenoviral vector type (median 6 [58]) than with the inactivated type (median 5 [47], p < 0.001). Adenoviral vector vaccines would increase the likelihood of headache by 2.38 times more than inactivated vaccines (odds ratio [OR] 2.38, 95% confidence interval [CI] 1.83-3.04, p < 0.001). Female sex and thyroid disease were significantly associated with headache related to COVID-19 vaccines (OR 1.52, 95% CI 1.16-1.99; OR 3.97, 95% CI 1.55-10.2, respectively).

CONCLUSION:

Recipients of the COVID-19 vaccine should be counseled that they may experience headaches, especially after the adenoviral vector type. However, the intensity of such headache is mild to moderate and can resolve within a few days. Based on the current study design and the potential recall bias, these results may not be generalizable and should be preliminary.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Headache Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Female / Humans / Young adult Language: English Journal: Headache Year: 2022 Document Type: Article Affiliation country: Head.14374

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Headache Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Female / Humans / Young adult Language: English Journal: Headache Year: 2022 Document Type: Article Affiliation country: Head.14374